Home›Stock Screener›Cohance Lifesciences

Cohance Lifesciences Share Price Today | Stock Price & Cohance Lifesciences Share Screener

COHANCE Pharmaceuticals & Biotechnology
Live Share Price NSE
₹456.40
▲ 4.80 (1.06%)
2026-11-18 00:00:00
Live Share Price BSE
₹456.40
▲ 4.75 (1.05%)
2026-11-18 00:00:00

As of November 18, 2026, the live Cohance Lifesciences share price (NSE: COHANCE) is ₹456.40 on NSE and ₹456.40 on BSE, up 1.06% from the previous close, with shares trading between ₹445.25 and ₹457.95 in today's trading session, and a 52-week range of ₹279.90–₹589.30. Track COHANCE market cap trends to gauge the company's total market size. Use the Cohance Lifesciences stock screener below to analyse P/E ratio, market cap, quarterly results, and more. See at what price today Cohance Lifesciences opened, then compare its market price and price volume with top gainers and top losers on the exchange. Record your trades in TickJournal's free trading journal and track your portfolio performance.

Key Statistics and Valuation Ratios

Over the trailing twelve months the company reported revenue of ₹617 and net income of ₹8, with EBITDA of ₹80, an operating margin of 13.0% and a profit margin of 1.3%.

Cohance Lifesciences Market Cap ₹17,278.10 Cr.
COHANCE P/E Ratio (TTM) -3049.70
Cohance Lifesciences P/B Ratio 4.47
EPS (TTM) ₹4.69
Dividend Yield 1.31%
Debt to Equity 0.12
COHANCE 52 Week High ₹589.30
Cohance Lifesciences 52 Week Low ₹279.90
Operating Margin 13.00%
Profit Margin 1.30%
COHANCE Revenue (TTM) ₹617.00
EBITDA ₹80.00
Net Income ₹8.00
Total Assets ₹5,730.00
Total Equity ₹4,034.00

Cohance Lifesciences Share Price Chart

Track the current stock price of Cohance Lifesciences with an interactive chart. Analyse COHANCE share price trends, closing price, trading volume, historical performance, and volatility using live market data across different timeframes, from the last 30 days to the full record — the complete Cohance Lifesciences stock quote in one place.

The quote of ₹456.40 sits between the 52-week low of ₹279.90 and the 52-week high of ₹589.30, and the latest session moved 1.06% from the previous close.

Cohance Lifesciences Company Profile - Fundamental Screener

Screen Cohance Lifesciences company fundamentals and business profile. Use our stock screener to analyze sector, industry, and key company metrics for COHANCE shares across the equity market and its stock price history, plus the wider market trend.

The company is classified under the Healthcare sector and the Pharmaceuticals & Biotechnology industry, with Umang Vohra listed as chairperson or CEO, and it trades under ISIN INE03QK01018.

Business Overview

Suven Pharmaceuticals Limited is an Indian biopharmaceutical company incorporated in 2018. It specializes in contract development and manufacturing operations for the global life sciences industry, focusing on New Chemical Entity-based intermediates, Active Pharmaceutical Ingredients, specialty chemicals, and formulated drugs. The company provides custom synthesis, process R&D, scale-up, and contract manufacturing...more

Company Details

Classification

Sector Healthcare
Industry Pharmaceuticals & Biotechnology
Sub-Sector Pharmaceuticals & Biotechnology
Segment E

Identifiers and Leadership

Chairperson/CEO Umang Vohra
ISIN INE03QK01018

Cohance Lifesciences Balance Sheet Screener

Screen COHANCE balance sheet fundamentals including assets, liabilities, and equity. Use our screener tool to analyze financial health and share price valuation metrics, then compare equity shares and the debt-to-equity rate against peers in the stock market.

For 2026, total assets were ₹5,730, up from ₹5,481 in 2025.

Latest statistics put total assets at ₹5,730 and shareholder funds at ₹4,034, with a leverage ratio of 0.12.

Item 2026 2025 2024 2023 2022 2021 2020 2019

Assets

Total Assets 5,730 5,481 2,254 1,966 1,830 1,475 1,173 783
Current Assets 0 0 0 0 0 0 0 0
Fixed Assets 3,369 3,107 670 663 534 441 357 271

Liabilities

Total Liabilities 0 0 0 0 0 0 0 0
Current Liabilities 1,050 983 97 72 92 74 128 35
Non-Current Liabilities 0 0 0 0 0 0 0 0

Shareholders' Equity

Total Equity 4,034 3,793 2,051 1,735 1,527 1,181 845 590
Share Capital 38 26 26 26 26 26 13 13
Reserves & Surplus 3,873 3,604 2,025 1,710 1,502 1,155 832 578

Cohance Lifesciences Income Statement Screener - Profit & Revenue Analysis

Screen Cohance Lifesciences income statement and profit fundamentals. Analyze COHANCE quarterly results. Cohance Lifesciences reports revenue growth, EBITDA, net profit margins, and EPS, and TickJournal's fundamental screener helps with stock evaluation and equity returns.

For 2026-Mar, revenue was ₹617 and net profit was ₹8, equal to earnings per unit of ₹0.51, at an operating margin of 13%.

In that period expenses were ₹537, interest cost ₹9 and tax ₹12. The next period listed, 2026-Jun, shows revenue of ₹435 and net profit of ₹-45.

Item 2026-Mar 2026-Jun 2026-Sept 2025-Mar 2025-Jun 2025-Sept 2025-Dec 2024-Mar 2024-Jun 2024-Sept 2024-Dec 2023-Mar 2023-Jun 2023-Sept 2023-Dec

Revenue and Expenses

Revenue 617 435 489 853 564 571 551 270 508 620 698 381 358 251 234
Expenses 537 421 441 627 445 435 454 180 363 398 439 198 181 133 154

Operating Costs and Margins

EBITDA 80 13 48 226 118 137 97 90 145 222 259 183 178 118 80
Operating Profit % 13.00% 0.00% 7.00% 25.00% 19.00% 22.00% 17.00% 29.00% 26.00% 34.00% 35.00% 47.00% 48.00% 42.00% 30.00%
Depreciation 51 50 50 54 45 44 47 17 31 38 44 12 13 12 13
Interest 9 7 8 10 10 9 9 2 10 10 11 5 1 1 2

Profit and Earnings

Profit Before Tax 20 -43 -11 161 63 84 41 71 103 174 205 166 164 105 66
Tax 12 2 -13 44 16 17 12 18 28 36 51 42 43 26 19
Net Profit 8 -45 2 117 46 66 29 53 75 138 154 124 121 80 47
EPS 0.51 -0.63 0.40 3.16 1.28 1.94 0.96 2.10 1.98 3.63 4.02 4.87 4.74 3.13 1.84

Cohance Lifesciences Cash Flow Screener - Liquidity Fundamentals

Screen COHANCE cash flow statements and liquidity fundamentals. Analyze operating, investing, and financing activities using our stock screener for share price strength and price trend assessment against the wider stock market and other stocks.

In 2026-March, operating activities generated ₹368, and net cash flow was an outflow of ₹48.

Over the same period, investing activities used ₹251 and financing activities used ₹165.

Item 2026-March 2025-March 2024-March 2023-March 2022-March 2021-March 2020-March 2019-March

Cash from Operations and Investing

Operating Activities 368 673 359 457 330 383 407 50
Investing Activities -251 -388 -362 -195 -136 -311 -414 -66

Financing and Net Cash

Financing Activities -165 -327 -14 -242 -156 -76 7 26
Net Cash Flow -48 -42 -18 20 37 -5 1 11

Cohance Lifesciences Shareholding Pattern Screener

See Cohance Lifesciences shareholding pattern with promoter, FII, and DII holdings. Check Cohance Lifesciences promoter holding and ownership changes for COHANCE on TickJournal, and see how institutional stock price moves affect the market.

In 2026-Mar, promoters held 57.49%, foreign institutions 5.59%, domestic institutions 21.79% and the public 7.04%, spread across 85,230 shareholders.

The shareholder count was 85,230 in 2026-Mar, compared with 99,149 in 2026-Jun.

Item 2026-Mar 2026-Jun 2026-Sept 2025-Mar 2025-May 2025-Jun 2025-Sept 2025-Dec

Promoter Holding

Promoter Holding 57.49% 57.49% 57.48% 50.10% 66.41% 66.41% 57.49% 57.49%

Institutional Investors

FII Holding 5.59% 6.50% 7.71% 11.05% 7.38% 7.23% 6.51% 6.02%
DII Holding 21.79% 20.09% 18.86% 16.60% 11.02% 11.40% 20.82% 21.57%

Government, Public and Others

Govt Holding 0.01% 0.01% 0.00% 0.01% 0.01% 0.01% 0.01% 0.01%
Public Holding 7.04% 7.71% 7.50% 9.68% 6.63% 6.40% 6.42% 6.76%
Other Holding 8.08% 8.21% 8.46% 12.55% 8.55% 8.55% 8.75% 8.16%
Shareholder Count 85,230 99,149 93,846 86,325 88,658 80,910 75,284 81,877

Dividend Yield Screener - Share Price & Share Analysis

Check the dividend history with payout and yield data. View dividend details including ex-dates, the dividend rate, and amounts paid by Cohance Lifesciences. Cohance Lifesciences dividend yield can be compared with peers and other stocks in the market.

The latest dividend recorded was ₹0.00 per unit for 2026-March, a yield of 0.00%, compared with ₹0.00 for 2025-March.

Dividends are listed for 10 periods, with the three most recent payouts at ₹0.00, ₹0.00 and ₹0.00 per unit.

Period Dividend Per Share Dividend Yield
2026-March ₹0.00 0.00%
2025-March ₹0.00 0.00%
2024-March ₹0.00 0.00%
2023-March ₹6.00 0.89%
2022-March ₹5.00 1.06%
2021-March ₹2.00 0.32%
2020-March ₹5.00 1.01%
2019-March ₹0.00 0.00%
2018-March ₹0.00 0.00%
2017-March ₹0.00 0.00%

Cohance Lifesciences Stock Index Membership - Nifty & Sensex

See which indices include Cohance Lifesciences stock. Check COHANCE index membership in NIFTY 50, SENSEX, and other indices on TickJournal, and compare the Nifty trend with the broader market trend.

The company is listed in 20 indices, including BSE 1000.

Among the benchmarks tracked are BSE 1000, BSE INDEX BSE HC, BSE INDEX BSE500, BSE INDEX MSL400.

Complete Index List

BSE 1000
BSE INDEX BSE HC
BSE INDEX BSE500
BSE INDEX MSL400
BSE INDEX SML250
BSE INDEX SMLCAP
BSE INDEX SMLSEL
NIFTY 500
NIFTY MIDSMALLCAP400 MOMENTUM QUALITY 100
NIFTY MIDSML 400
NIFTY MIDSML HLTH
NIFTY MNC
NIFTY MULTI MFG
NIFTY SMALLCAP250 MOMENTUM QUALITY 100
NIFTY SMLCAP 250
NIFTY TOTAL MKT
NIFTY500 EQUAL WEIGHT
NIFTY500 MOMENTUM 50
NIFTY500 MULTICAP
NIFTY500 MULTICAP MOMENTUM QUALITY 50

Cohance Lifesciences Market Events Screener - Corporate Actions

Get Cohance Lifesciences corporate actions including splits, bonuses, and buybacks disclosed to the exchange. Check Cohance Lifesciences stock events that may affect COHANCE share price, along with derivatives, futures and options activity and sector gainers.

15 corporate actions are listed, the most recent entry being Quarterly Result Announcement dated November 6, 2026, with a record date of November 6, 2026.

It is followed by Annual General Meeting dated September 17, 2026 and Quarterly Result Announcement dated August 5, 2026.

Announcement Date Record Date Event Type Information Price Impact
2026-11-06 2026-11-06 Quarterly Result Announcement NA -0.03%
2026-09-17 2026-09-17 Annual General Meeting NA 1.89%
2026-08-05 2026-08-05 Quarterly Result Announcement NA -2.94%
2026-05-12 2026-05-12 Quarterly Result Announcement NA 5.46%
2026-02-12 2026-02-12 Quarterly Result Announcement NA -33.96%
2025-11-12 2025-11-12 Quarterly Result Announcement NA -20.48%
2025-09-19 2025-09-19 Annual General Meeting NA -6.87%
2025-08-13 2025-08-13 Quarterly Result Announcement NA -5.19%
2025-05-28 2025-05-28 Quarterly Result Announcement NA -5.13%
2025-05-07 2025-05-07 Change Of Name NA 0.00%
2025-02-12 2025-02-12 Quarterly Result Announcement NA -5.54%
2024-11-28 2024-11-28 Extraordinary General Meeting NA -0.62%
2024-11-12 2024-11-12 Quarterly Result Announcement NA 4.44%
2024-08-09 2024-08-09 Annual General Meeting NA 16.74%
2023-12-15 2023-12-15 Annual General Meeting NA 17.68%

Cohance Lifesciences Competitors Screener - Peer Stocks Comparison

Screen COHANCE competitors and compare share prices across peer stocks. Use our screener to analyze sector peers, fundamentals, and relative performance, from valuation and price target to the future price outlook, for better stock selection in a changing stock market.

The comparison table covers 10 companies in the Healthcare sector, shown with market capitalisation, P/E ratio, revenue, growth, net profit and RSI.

Company Market Cap P/E Ratio Revenue YoY Growth Net Profit RSI
Sun Pharmaceutical 448,676 40.80 61,674 12.69% 11,565 60.46
Divis Laboratories 295,997 87.70 11,067 13.95% 2,568 68.76
Torrent Pharmaceuticals 177,586 85.00 13,886 20.34% 2,138 47.23
Laurus Labs 126,325 89.90 6,868 22.01% 890 57.04
Zydus Life Science 120,119 27.60 27,658 17.64% 5,026 55.91
Dr Reddys Laboratories 115,854 41.80 35,059 3.90% 4,158 71.26
Cipla 112,131 39.50 29,045 2.24% 3,870 53.06
Mankind Pharma 107,805 47.90 14,636 14.85% 1,938 61.37
Aurobindo Pharma 103,229 25.80 34,145 5.56% 3,503 60.39
Lupin 89,172 17.30 29,039 26.75% 5,356 39.39

Cohance Lifesciences Company Announcements - News & Reports Screener

Screen COHANCE latest company announcements and news updates. Filter stock news, results, and material events using our screener for share price impact analysis, and review the option chain for related stocks. Compare other stocks in the same sector.

20 recent announcements are listed, the latest dated November 14, 2026.

The next most recent announcements are dated November 14, 2026 and November 13, 2026.

Date Update Actions
2026-11-14 Revised Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 2011 -
2026-11-14 Revised Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 2011 -
2026-11-13 Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation -
2026-11-13 Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome -
2026-11-13 Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 2011 -
2026-11-13 Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 2011 -
2026-11-09 Announcement under Regulation 30 (LODR)-Investor Presentation -
2026-11-09 Announcement under Regulation 30 (LODR)-Newspaper Publication -
2026-11-09 Update On USFDA Inspection For CompanyS Pashamylaram Manufacturing Facility -
2026-11-09 Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome -
2026-11-06 Outcome Of The Board Meeting -
2026-11-06 Board Meeting Outcome for Outcome Of The Board Meeting -
2026-11-06 Grant Of Stock Options To Certain Eligible Employees Of The Company And Allotment Of Equity Shares Pursuant To Exercise Of Stock Options -
2026-11-06 General Announcement -
2026-11-03 Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation -
2026-10-27 Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation -
2026-10-26 Board Meeting Intimation for Considering The Unaudited Financial Results (Standalone And Consolidated) Of The Company For The Quarter And Half Year Ended 30 September 2026 -
2026-10-12 General Updates -
2026-10-09 Grant Of Stock Options To Certain Eligible Employees Of The Company -
2026-10-09 Announcement under Regulation 30 (LODR)-Change in Management -

Frequently Asked Questions

How is the company valued right now?

The current quote is ₹456.40, within a 52-week range of ₹279.90 to ₹589.30. The P/E ratio is -3049.70 and the P/B ratio is 4.47, with earnings per unit of ₹4.69. Market capitalisation stands at ₹17,278.10 Cr and the dividend yield is 1.31%. The company operates in the Healthcare sector, in the Pharmaceuticals & Biotechnology industry, so compare these ratios with its sector peers in the table above.

About This Data

Quotes are sourced from the NSE and the BSE. Key statistics were last updated on November 19, 2026. This page covers 8 balance sheet periods, 15 income statement periods, 8 cash flow years and 8 shareholding periods. Information is provided for research and is not investment advice.